Prostate-specific antigen

Oncternal Announces Enrollment Completed and Dosing Initiated for Fifth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

Retrieved on: 
torsdag, maj 30, 2024
Patient, SRC, Prostate-specific antigen, Therapy, Safety, SAN, PSA, Pharmaceutical industry

Patients in the fifth cohort are receiving ONCT-534, the company’s dual-action androgen receptor inhibitor (DAARI), at a dose of 600 mg taken orally once each day.

Key Points: 
  • Patients in the fifth cohort are receiving ONCT-534, the company’s dual-action androgen receptor inhibitor (DAARI), at a dose of 600 mg taken orally once each day.
  • The decision to proceed to this higher dose level was made by the study’s Safety Review Committee (SRC) after reviewing data from the fourth dose level of 300 mg ONCT-534 daily.
  • “We are encouraged by the rapid enrollment in the dose escalation portion of our Phase 1/2 study with ONCT-534.
  • We continue to open new sites and patient demand continues to be strong,” said Salim Yazji M.D., Chief Medical Officer at Oncternal Therapeutics.

Bayer presents latest data from oncology portfolio at 2024 ASCO Annual Meeting

Retrieved on: 
torsdag, maj 16, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, Clinical Trials, Darolutamide, Patient, Survival, Disease, Phase, NTRK, Risk, TRK, HER2, Docetaxel, Prostate cancer, Prostate-specific antigen, Safety, NSCLC, BCR, ADT, PSA, Metastasis, ASCO, Abstract, Society, Mutation, Annual general meeting, Pharmaceutical industry

Bayer will present new data across its oncology portfolio at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago, from May 31 – June 4, 2024.

Key Points: 
  • Bayer will present new data across its oncology portfolio at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago, from May 31 – June 4, 2024.
  • The breadth of new data in different tumor types underscores Bayer’s ambition to deliver innovative and effective oncological therapies in areas with the highest unmet medical needs.
  • Prostate cancer is a key focus for Bayer Oncology, with data to be presented on NUBEQA® (darolutamide) and XOFIGO® (radium Ra 223 dichloride) across multiple stages of the disease.
  • An overview of the ongoing investigational Phase III ARASTEP trial in hormone sensitive prostate cancer patients with high-risk biochemical recurrence will also be presented.

14 Studies Presented at AUA 2024 Show Decipher Tests’ Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease Understanding

Retrieved on: 
måndag, maj 6, 2024
Oncology, Health, Technology, Health Technology, Genetics, Artificial Intelligence, Biotechnology, RUO, University, Prostate, NCCN, RC, International, RP, Risk, Grade, American Urological Association, Survival, Neoadjuvant therapy, PSA, Columbia University, Integration, Research, Pathology, GSC, Prostate cancer, Prostate-specific antigen, University of Michigan, Patient, NOC, Urology, Intelligence, AUA, MRI, Biopsy, Gene expression, Diagnosis, MUSIC, Waiting, Bladder cancer, Radical, Medical imaging

(Nasdaq: VCYT), a leading cancer diagnostics company, today announced that data from 14 presentations at AUA 2024, the annual meeting of the American Urological Association, show that the Decipher Prostate and Decipher Bladder Genomic Classifiers provide better prognostic information for patients with prostate and bladder cancer, compared to standard approaches.

Key Points: 
  • (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that data from 14 presentations at AUA 2024, the annual meeting of the American Urological Association, show that the Decipher Prostate and Decipher Bladder Genomic Classifiers provide better prognostic information for patients with prostate and bladder cancer, compared to standard approaches.
  • They also show that the research-use-only Decipher GRID (Genomic Resource for Intelligent Discovery) tool is helping to advance scientific understanding of these diseases.
  • Summary: The Decipher Prostate Genomic Classifier is associated with adverse pathology in patients eligible for Active Surveillance (AS) who were treated with radical prostatectomy (RP).
  • Podium Presentation PD42-03 : Understanding Population-Wide Genomic Risk Distribution and Integrating Clinical-Genomic Risk for Prognostication in Prostate Cancer.

Cleveland Diagnostics Signs Distribution Agreement with Dow BioMedica to Bring Prostate Cancer Test, IsoPSA, to Korea

Retrieved on: 
lördag, april 13, 2024
Protein, Risk, Dow, PSA, University, Prostate cancer, Prostate-specific antigen, Diagnosis, Patient, Physician, Biopsy, Cancer, Biotechnology, Medical imaging

Under this agreement, Dow BioMedica will exclusively distribute Cleveland Diagnostics’ IsoPSA prostate cancer test in Korea.

Key Points: 
  • Under this agreement, Dow BioMedica will exclusively distribute Cleveland Diagnostics’ IsoPSA prostate cancer test in Korea.
  • Dr. Arnon Chait, President & CEO of Cleveland Diagnostics, expressed enthusiasm about the collaboration, stating, “We are thrilled to partner with Dow BioMedica to expand the availability of IsoPSA in Korea.
  • “We are excited to add IsoPSA to our portfolio of life science offerings,” added Mr. YG Shin, CEO of Dow BioMedica.
  • “By integrating this groundbreaking technology into our suite of diagnostic solutions, we aim to empower healthcare providers in Korea with advanced tools for early prostate cancer detection.”

FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer

Retrieved on: 
tisdag, april 2, 2024
Neutropenia, Prostate cancer, Survival, RECIST, Prostate-specific antigen, Patient, SAN, Neoplasm, MMAE, Weight loss, Publishing, Peripheral neuropathy, University, CD46, Spacecraft, Society, Safety, ASCO, Adenocarcinoma, Fatigue, ADC, PSA, FDA, Fortis, Lead, Food, Pharmaceutical industry

“We are delighted to showcase the latest encouraging clinical data from the FOR46-001 Phase 1 ADC trial,” said Deyaa Adib, M.D., Chief Medical Officer of FibroGen.

Key Points: 
  • “We are delighted to showcase the latest encouraging clinical data from the FOR46-001 Phase 1 ADC trial,” said Deyaa Adib, M.D., Chief Medical Officer of FibroGen.
  • In the dose-expansion arm of the trial, patients were treated at the 2.7 mg/kg adjusted body weight dosing (AjBW) until disease progression.
  • The completed Phase 1 trial includes a total of 56 patients from the dose-escalation and dose-expansion cohorts.
  • These findings warrant further investigation and hold promise for addressing the therapeutic needs of patients with CD46 positive prostate cancer.

Enhancing Prostate Cancer Screening: AI, Imaging and Clinical Innovations, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
onsdag, mars 13, 2024
Diagnosis, Algorithm, MRI, Prostate cancer, Radiology, Medical imaging, Magnetic resonance imaging, Partnership, Prostate-specific antigen, PET, Bachelor of Science, Artificial intelligence, AI, Doctor of Philosophy, MBBS, University College London, Workforce, PSA

TORONTO, March 13, 2024 /PRNewswire-PRWeb/ -- This webinar will delve into how prostate cancer screening has been performed to date and the latest clinical research evaluating new diagnostic tests. The featured speakers will also discuss the critical role artificial intelligence (AI) will play in combination with clinical and imaging tests to deliver sustainable, patient-centric screening pathways.

Key Points: 
  • In this free webinar, learn about the evolution of prostate cancer screening and the shift to magnetic resonance imaging (MRI)-based diagnostic tools for more accurate screening.
  • The featured speakers will share insights into the development of AI-based algorithms in prostate cancer, including best practices and pitfalls.
  • The speakers will also discuss ongoing clinical studies shaping the future of prostate cancer detection and treatment.
  • TORONTO, March 13, 2024 /PRNewswire-PRWeb/ -- This webinar will delve into how prostate cancer screening has been performed to date and the latest clinical research evaluating new diagnostic tests.

Xencor Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
tisdag, februari 27, 2024
Biotechnology, Pharmaceutical, Health, Oncology, CD20, NSCLC, Cancer, J&J, Immune system, Alanine transaminase, Autoimmune disease, Research, ENPP3, Investment, ALT, PSMA, Cell, Antibody, Autoimmune hepatitis, Safety, Telephone, Vir, Lymphoid leukemia, Rash, Patient, PSA, RECIST, CLDN6, Diagnosis, Prostate-specific antigen, G&A, Workforce, CD28, Prostate cancer, Pharmaceutical industry

Both programs entered Phase 1 clinical development during the fourth quarter of 2023, and Xencor received $20 million in development milestones.

Key Points: 
  • Both programs entered Phase 1 clinical development during the fourth quarter of 2023, and Xencor received $20 million in development milestones.
  • In the fourth quarter of 2023, Xencor completed enrollment in subcutaneous dose-escalation cohorts of a Phase 1 study evaluating plamotamab.
  • Financial Results for the Fourth Quarter and Full Year Ended December 31, 2023
    Cash, cash equivalents, and marketable debt securities totaled $697.4 million as of December 31, 2023, compared to $584.5 million on December 31, 2022.
  • Total revenue for the fourth quarter ended December 31, 2023 was $44.7 million compared to $21.6 million for the same period in 2022.

Blue Earth Therapeutics Announces Publication of Results from Independent Clinical Experience with 177Lu-rhPSMA-10.1 in Treatment of Metastatic Castrate Resistant Prostate Cancer

Retrieved on: 
tisdag, februari 20, 2024
Science, Radiology, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Therapeutic index, DOI, Nuclear medicine, Prostate cancer, Neoplasm, Isotope, Teaching hospital, Physician, Safety, Food, PSMA, Treatment, Hope, Manuscript, Therapy, Patient, Optimism, Journal, PSA, Legislation, Prostate-specific antigen, Metastasis, Medical imaging

The manuscript, “First Safety and Efficacy Data with the Radiohybrid 177Lu-rhPSMA-10.1 for the Treatment of Metastatic Prostate Cancer,” has been published in the Journal of Nuclear Medicine (DOI https://doi.org/10.2967/jnumed.123.266741 ).

Key Points: 
  • The manuscript, “First Safety and Efficacy Data with the Radiohybrid 177Lu-rhPSMA-10.1 for the Treatment of Metastatic Prostate Cancer,” has been published in the Journal of Nuclear Medicine (DOI https://doi.org/10.2967/jnumed.123.266741 ).
  • In the 4 consecutive patients with metastatic prostate cancer who were evaluated, when looking at radiologic progression free survival (rPFS), 2 patients had not progressed at 24 and 18 months of follow-up.
  • 177Lu-rhPSMA-10.1 is an investigational radiohybrid (rh) Prostate-Specific Membrane Antigen-targeted radiopharmaceutical for the treatment of prostate cancer, and the lead candidate in Blue Earth Therapeutics’ development of next generation therapeutic radiopharmaceuticals.
  • “These promising clinical data give us further optimism in advancing 177Lu-rhPSMA forward in clinical development, with the hope to help treat patients with metastatic prostate cancer.

Prostate Cancer Prevention and Treatment Technologies: Comprehensive Global Market Analysis - ResearchAndMarkets.com

Retrieved on: 
måndag, februari 12, 2024
Health, Oncology, Incidence, Carcinoid, Prostate cancer, PARP, DRE, Treatment, Sarcoma, Genetic testing, RALP, Risk assessment, Patient, PSA, Diagnosis, Prostate, Male, Prostate-specific antigen, Cancer, Medical imaging

The "Prevention and Treatment of Prostate Cancer: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Prevention and Treatment of Prostate Cancer: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.
  • The global market for prostate cancer care reached $35.3 billion in 2022.
  • The global market for prostate cancer screening and detection is projected to grow at a CAGR of 5.8% to reach $19.8 billion by the end of 2028.
  • Continued incidence of prostate cancer, the world's growing elderly population, and increasing therapeutic innovations are key driving factors in the market for prostate cancer drugs.

Additional ODM-208/MK-5684 Phase II data presented at ASCO-GU 2024

Retrieved on: 
fredag, januari 26, 2024
Senior, Hormone replacement therapy, Patient, Prostate cancer, ASCO, Prostate-specific antigen, CYP11A1, LBD, Mutation, Adrenal insufficiency, PSA, Safety, Research, Cancer, Growth, Pharmaceutical industry

Orion presented yesterday at the 2024 ASCO GU Cancers Symposium a poster with additional data from the ongoing Phase II CYPIDES trial evaluating the safety and efficacy of ODM-208 (or MK-5684), an investigational, oral CYP11A1 inhibitor, in heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC) with and without AR-LBD mutations.

Key Points: 
  • Orion presented yesterday at the 2024 ASCO GU Cancers Symposium a poster with additional data from the ongoing Phase II CYPIDES trial evaluating the safety and efficacy of ODM-208 (or MK-5684), an investigational, oral CYP11A1 inhibitor, in heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC) with and without AR-LBD mutations.
  • The new data reports initial results in an extension cohort of mainly AR-LBD wild-type patients combined with previously reported phase 2 data (AR-LBD mutation-positive only).
  • Data from the Phase II CYPIDES trial suggest that ODM-208/MK-5684 potently inhibits all steroid-hormone biosynthesis with observed antitumor activity in a heavily pretreated mCRPC population, especially in patients with AR-LBD mutations.
  • In Phase II CYPIDES, at data cut-off, a total of 134 previously treated mCRPC patients received 5mg of ODM-208/MK-5684 twice a day with glucocorticoid/mineralocorticoid replacement and ongoing androgen-deprivation therapy.